GGrantIndex
← Search

Cancer GENETICS AND EPIGENETICS

$31,270P30FY2014CANIH

Emory University, Atlanta GA

Investigators

Linked publications, trials & patents

Trial NCT07405476Trial NCT07213154Trial NCT07174570Trial NCT07155317Trial NCT07150546Trial NCT07140679Trial NCT07112690Trial NCT07104240Trial NCT07101445Trial NCT06914999Trial NCT06868433Trial NCT06865768Trial NCT06799481Trial NCT06760507Trial NCT06731270Trial NCT06709534Trial NCT06708351Trial NCT06674863Trial NCT06662058Trial NCT06650579Trial NCT06636734Trial NCT06595160Trial NCT06583148Trial NCT06541158Trial NCT06534125Trial NCT06495125Trial NCT06492759Trial NCT06492070Trial NCT06423326Trial NCT06328699Trial NCT06328686Trial NCT06324240Trial NCT06254911Trial NCT06132685Trial NCT06105918Trial NCT06008730Trial NCT06006013Trial NCT05998135Trial NCT05877859Trial NCT05873608Trial NCT05798507Trial NCT05779943Trial NCT05756569Trial NCT05733351Trial NCT05526872Trial NCT05514912Trial NCT05513859Trial NCT05506982Trial NCT05493566Trial NCT05488145Trial NCT05464810Trial NCT05391750Trial NCT05387915Trial NCT05368428Trial NCT05346692Trial NCT05341349Trial NCT05320406Trial NCT05315687Trial NCT05310448Trial NCT05274763Trial NCT05250895Trial NCT05245682Trial NCT05244239Trial NCT05208307Trial NCT05204160Trial NCT05103904Trial NCT05091866Trial NCT05086731Trial NCT05039073Trial NCT05017610Trial NCT04908709Trial NCT04895592Trial NCT04890236Trial NCT04883437Trial NCT04878029Trial NCT04848519Trial NCT04776395Trial NCT04762199Trial NCT04754945Trial NCT04750473Trial NCT04731376Trial NCT04725903Trial NCT04676087Trial NCT04590664Trial NCT04585724Trial NCT04524702Trial NCT04483206Trial NCT04433949Trial NCT04428671Trial NCT04393350Trial NCT04366791Trial NCT04361552Trial NCT04352205Trial NCT04348292Trial NCT04340882Trial NCT04278118Trial NCT04276194Trial NCT04262869Trial NCT04191421Trial NCT04144127

Abstract

PROJECT SUMMARY: The goal of the Cancer Genetics and Epigenetics (CGE) Program is to better understand the fundamental mechanisms underlying genetic and epigenetic instability and its contribution to the initiation and progression of human tumors. In pursuit of this goal, the program organizes its research efforts into three areas of focus: 1) DNA damage and repair and genome instability; 2) epigenetics and gene regulation; and 3) cancer genetics /genomics. The CGE Program consists of 29 core members from 13 academic departments and three schools across Emory University, including the School of Medicine, the School of Public Health and Emory College. CGE Program members currently have $15,110,592 in research grant funding (annual direct costs), of which $12,849,105 is peer-reviewed and $4,277,290 (34%) is NCI-funded. Program members have published 227 cancer-related publications in the cun-ent project period. Among these, 12% and 25% represent intra- and inter-programmafic and interactions, respectively. In the current project period, discovery efforts have led to the identification of key genes whose mutation or altered expression contribute to cancer initiation and progression. Basic discoveries in the area of cancer epigenetics have prompted early small molecule screening efforts to identify novel targeted agents. Program development and key recruitments have strengthened and enhanced intra-programmatic activities in the areas of human radiation carcinogenesis, DNA damage/repair, and cancer genomics. This has been leveraged into several new multi-investigator grants and has provided key translational avenues for the program through increased inter-programmatic activities and cross-cutting genomics initiatives. Successful genomic studies resulted in the molecular classification of tumors and the identification of genes, gene signatures, and clinical factors with prognostic value in prostate, breast, brain, and lung malignancies. The Cancer Genetics and Epigenetics Program facilitates scientific collaborations and cancer research discoveries and has positioned itself for continued development in the forthcoming project period.

View original record on NIH RePORTER →